A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors
J. R. Infante, R. Kurzrock, J. Spratlin, H. A. Burris, S. G. Eckhardt, J. Li, K. Wu, J. M. Skolnik, L. Hylander-Gans, A. Osmukhina, D. Huszar, R. S. HerbstVolume:
69
Language:
english
Pages:
8
DOI:
10.1007/s00280-011-1667-z
Date:
January, 2012
File:
PDF, 338 KB
english, 2012